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Objectives: To use databases of the US Veterans Health Administration (VHA) to describe the impact
of Parkinson’s disease on health related quality of life (HRQoL) of veterans; to compare the HRQoL of
veterans with Parkinson’s disease with that of veterans reporting eight other neurological or chronic
conditions; and to estimate the unique effect of Parkinson’s disease on HRQoL.
Methods: Respondents to the VHA 1999 large national health survey of veteran enrollees with a diag-
nosis of Parkinson’s disease in VHA treatment files for the fiscal years 1997–1999 were identified by
merging databases. The survey incorporated the Veterans SF-36, a well validated generic measure of
HRQoL and functional status. This was used to compare patient groups. Mean physical (PCS) and men-
tal (MCS) component summary scores were calculated for Parkinson’s disease and eight other diseases
by multivariable regressions that adjusted for age, sex, race, education, and 15 mental and physical
co-morbid conditions that were self reported in the survey.
Results: Of 887 775 survey respondents, 14 530 (1.64%) had a Parkinson’s disease diagnosis. Con-
trolling for sociodemographic factors and co-morbidities, veterans with Parkinson’s disease had PCS
and MCS below veterans with angina/coronary heart disease, arthritis, chronic low back pain, con-
gestive heart failure, diabetes, and stroke. Veterans with spinal cord injury reported slightly lower PCS
than veterans with Parkinson’s disease (32.38 v 32.72; 0.03 of 1 SD). Veterans with depression
reported markedly lower MCS than veterans with Parkinson’s disease (35.94 v 41.48; 0.55 of 1 SD).
The unique effect of having Parkinson’s disease on HRQoL was to lower PCS and MCS by 4.10 and
3.42 points (0.41 and 0.34 of 1 SD), respectively.
Conclusions: The analysis quantifies the negative impact of Parkinson’s disease on HRQoL, after con-
trolling for sociodemographic factors and co-morbidities. Compared with eight other chronic
conditions, Parkinson’s disease imposes a relatively heavy burden on US veterans in the VHA health
care system.
Patients’ perceptions about how their illness affects themin their daily lives can differ from those of theirpractitioners1–3 and informal caregivers.4 It is particularly
important that clinicians understand how patients experience
chronic and often incurable conditions such as Parkinson’s
disease, where the goals of treatment are to optimise their
quality of life.5 Parkinson’s disease gives rise to a range of
physically disabling and socially distressing symptoms.6 7
Empirical information about the impact of disease can be
gathered from patients by measures of health related quality
of life (HRQoL).8 In combination with clinical indicators,
HRQoL data contribute to the appreciation of the overall
impact of disease on patients.9
Formal study of HRQoL is only about 25 years old, and has
grown substantially over the last decade.8 Although method-
ological and conceptual challenges remain,5 10 HRQoL as an
outcome has become an important standard for use in health
care interventions. It can also be used as a basis for assessing
the health status of populations, and to judge the burden of
disease by comparing clinical groups with the general popula-
tion. At an individual level, HRQoL has been shown to be a
sound predictor of mortality and morbidity,11 although
available measures are not always appropriate for use in rou-
tine clinical practice.12
The most commonly used HRQoL instruments are meas-
ures which characterise patients using multidimensions or
scales.13 A distinction is drawn between generic and disease
specific measures of HRQoL.3 Although there is debate about
the appropriate dimensions to include,14 generic assessments
often cover measures of physical functioning, independence of
living, emotional/mental wellbeing, and the effects of disease
on work and social activity. They allow broad population level
analyses and comparisons between patient groups, but they
do not focus on the special features of particular conditions
that cause concern to the sufferers.
The Veterans Administration health care system (VHA) is
one of the largest integrated systems nationally in the USA,
with around 145 medical centres in the 50 states. This system,
which is federally funded, provides comprehensive care to
most veteran patients with service connected disabilities or
who qualify economically. Veterans who use the VHA tend to
be more disabled, economically disadvantaged, and have more
complex medical and mental health problems than the
general US population or veterans who do not use the VHA
system.15 Because the VHA recognises the importance of
monitoring the health outcomes of veterans using measures of
functional status, HRQoL assessments are increasing on a
national basis. One of the most widely used generic measures
in the VHA is the Veterans SF-36 (V/SF-36), adapted and
modified from the medical outcomes study (MOS) version of
the SF-36.16–19
In this study we used the V/SF-36 to evaluate the impact of
Parkinson’s disease on HRQoL in a large VHA national sample
(n = 14 530) of veterans diagnosed with Parkinson’s disease.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Abbreviations: HRQoL, health related quality of life; MCS, mental
component summary score of SF-36; MOS, medical outcomes study; PCS,
physical component summary score of SF-36; RE, role, emotional; RP,
role, physical; SF-36, short form 36 item health status questionnaire;
VHA, Veterans Administration health care system; V/SF-36, Veterans
short form 36 item health status questionnaire
See end of article for
authors’ affiliations
. . . . . . . . . . . . . . . . . . . . . . .
Correspondence to:
Ms Heather Gage,
Department of Economics,
University of Surrey,
Guildford GU2 7XH,
Surrey, UK;
h.gage@surrey.ac.uk
Received 5 March 2002
In revised form
3 September 2002
Accepted
1 November 2002
. . . . . . . . . . . . . . . . . . . . . . .
163
www.jnnp.com
The statistical power from this large number of subjects has
advantages over previous studies that collected data from
fewer than 250 respondents.20–22 The self reported HRQoL of
veterans with Parkinson’s disease is compared with that of the
veterans without Parkinson’s disease, and also with that of
veterans reporting eight other neurological or chronic
diseases. To our knowledge, there have been no previous stud-
ies that have examined the relative illness burden of
Parkinson’s disease. Many people with chronic disease suffer
from multiple conditions, and the use of a generic instrument
enables the health status of these people to be monitored.23 We
used multivariable statistical techniques to control for
sociodemographic differences and co-morbid conditions so
that the independent impact of particular diseases can be cal-
culated and the unique effect of Parkinson’s disease on HRQoL
can be estimated.
METHODS
Data
The study population is US veterans enrolled in the VHA. All
veterans have the option of enrolling in VHA, and eligibility is
defined by seven priority categories:
• groups 1, 2, and 3: veterans with service connected disabil-
ity of > 50%, 30–40%, and 10–20% respectively, and former
prisoners of war;
• group 4: veterans who are catastrophically disabled, house-
bound, needing aid and attendance;
• group 5: veterans with income and net worth below estab-
lished thresholds;
• group 6: veterans of World War I, “agent orange,” and “Gulf
War syndrome”;
• group 7: veterans who do not qualify under priority areas
1–6 but may make co-payments for VHA services according
to fixed schedules.
Overall, 72.6% of VHA enrollees have alternative health care
coverage besides VHA: 52.7% have Medicare (federal coverage
for the aged or disabled), 19.1% have only private insurance,
and 1% have only Medicaid (public coverage for the indigent).
In 1999, 38.2% of enrollees exclusively used VHA for health
care.24
Inspection of VHA administrative data for the fiscal years
1997 to 1999 showed there were 55 637 veterans with a diag-
nosis of Parkinson’s disease (ICD-9-CM codes 332.0: Parkin-
son’s disease; 333.0: other degenerative diseases of the basal
ganglia, including Parkinsonian syndromes; 333.1: essential
and other specified forms of tremor). This file was merged
with data from the 1999 VHA large national health survey of
veteran enrollees,19 which had randomly sampled 1.4 million
VHA enrollees, stratified for priority status, from a total VHA
population of approximately 3.5 million, between July 1999
and January 2000. In this way we were able to identify survey
respondents with a recent diagnosis of Parkinson’s disease.
The core section of the 1999 VHA large national health sur-
vey, which was completed by all respondents, collected data by
means of a structured questionnaire on sociodemographic
factors and health status. To measure the prevalence of
chronic diseases, veterans were asked whether or not a doctor
had ever told them they had each of 15 conditions
(angina/coronary heart disease, arthritis, benign prostatic
hypertrophy, cancer, chronic low back pain, chronic lung
disease, congestive heart failure, depression, diabetes, hyper-
tension, myocardial infarction, post-traumatic stress disorder,
schizophrenia, spinal cord injury, stroke). Health status was
measured using V/SF-36.
As shown in table 1, SF-36 comprises 36 items, which are
combined into eight scales and summarised into the physical
(PCS) and mental summary (MCS) scores. Items from each
SF-36 scale were summed and raw scores were rescaled with
a standard range 0 (worst) to 100 (best). The eight scales were
combined into the two component summaries (PCS and
MCS), using weights derived from a national probability sam-
ple. Each summary was then standardised with a mean of 50
and a standard deviation of 10. This process allows compari-
son across populations. Summaries have a consistent power
advantage over scales, given their increased precision.25
The reliability and validity of the modified SF-36 is well
established in VHA populations and, as in the MOS SF-36 ver-
sion, normalised to a US population.25–32 The V/SF-36 uses five
point ordinal choices (no, none of the time, to yes, all of the
time) in the physical role limitations (RP) and emotional role
limitations (RE) scales, instead of dichotomised two point
choices (yes/no), and adds about 5% to the precision of the
PCS and MCS scores compared with the MOS SF-36.18 19 26
In addition to the core questionnaire, the VHA large
national health survey included five modules—each allocated
to a random 20% of sample members—on smoking and alco-
hol, diet and physical activity, satisfaction with care and the
doctor–patient relationship, social support, and health care
insurance and utilisation. Two sets of weights were applied to
responses: first, to make the samples representative of the
complete veteran enrollee population; and second, to correct
for the extent that responses were not randomly distributed
across all demographic groups.
Analysis
First, the socioeconomic, demographic, health, and service utili-
sation characteristics of survey respondents with Parkinson’s
Table 1 SF-36 items, scales, and component summaries*
Scales (items)
Component summary
measure Scales (items)
Component summary
measure
Physical functioning (PF) (10
items: ability to undertake
activities, carry, walk, climb
stairs, bend, kneel, bathe,
dress)
Physical component
summary (PCS)
Vitality (VT) (four items:
energy, fatigue)
Mental component
summary (MCS)
Role physical (RP) (four items:
physical limitations to activity)
Social functioning (SF) (two
items: engagement in social
activity)
Bodily pain (BP) (two items:
magnitude and interference of
pain)
Role emotional (RE) (three
items: emotional limitations
to activities)
General health (GH) (four
items: perceptions of health
status)
Mental health (MH) (five
items: nervous, peaceful,
sad, happy)
*Adapted from references 18 and 25.
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disease were compared with those of respondents without a
diagnosis of Parkinson’s disease using χ2 tests of association.
Second, differences in HRQoL between groups of survey
respondents were assessed. We used SUDAAN, a software
package specifically designed for statistical testing of complex
sample datasets.33 Two multivariable least squares regression
models (for PCS and MCS) calculated the mean V/SF-36 sum-
mary scores for veterans with Parkinson’s disease and
veterans with eight other chronic diseases (angina/coronary
heart disease, arthritis, chronic low back pain, congestive
heart failure, depression, diabetes, spinal cord injury, stroke).
These eight neurological and chronic conditions were selected
for comparison with Parkinson’s disease from the 15 self
reported by survey respondents, because of their established
adverse effects on HRQoL.19
Twenty variables were entered into the regression models:
four sociodemographic characteristics (age, sex, race, educa-
tion) that are known to influence HRQoL,28 a dichotomised
variable showing whether or not respondents had a diagnosis
of Parkinson’s disease in VHA treatment files in the fiscal years
1997 to 1999, and 15 dichotomised variables for whether or
not respondents had self reported each of the chronic
conditions included in the survey. The age and race variables
were each split into three categories for the purposes of the
regression analysis (18–50, 51–65, > 65 years; white, black,
other races). Education was divided into two categories,
defined by whether or not the respondent had received more
than 12 years of education.
The regression coefficients for each disease indicate an
effect size: the difference in PCS (or MCS) between veterans
with the disease and veterans without it, after controlling for
the effect of four sociodemographic features and 15 co-
morbidities. The effect size indicates the independent or
unique impact of each disease on HRQoL. Results are
presented here for Parkinson’s disease and the eight selected
comparison conditions.
RESULTS
Descriptive analysis of sample
Of 887 775 respondents to the 1999 VHA large national health
survey (overall response rate 63.1%), 14 530 (1.6%) had a
diagnosis of Parkinson’s disease in VHA treatment files for fis-
cal years 1997 to 1999.
The characteristics of survey respondents with a diagnosis
of Parkinson’s disease are compared with those of respondents
without Parkinson’s disease in table 2. As might be expected
with denominators of this magnitude, differences between
groups were significant for all characteristics (p < 0.001), but
small differences may not be important. Compared with other
veterans, those with Parkinson’s disease were more likely to be
65 years of age or older, white, retired, have had 12 or fewer
years of education, be catastrophically disabled, be enrolled in
Medicare, rely exclusively on the VHA for health care services,
and report recent deteriorations in physical and mental
health.
Veterans with Parkinson’s disease reported, on average, 4.0
co-morbid conditions, compared with 3.2 among veterans
without Parkinson’s disease. All recorded conditions were sig-
nificantly more prevalent among veterans with Parkinson’s
disease (p < 0.001). Table 3 shows that the largest differences
between subjects with and without a diagnosis of Parkinson’s
disease were recorded for stroke, arthritis, benign prostatic
hypertrophy, depression, and heart problems. Unadjusted
mean PCS and MCS scores for veterans with Parkinson’s dis-
ease were, respectively, 6.9 and 5.7 points (0.69 and 0.57 of
1 SD) below those of veterans without Parkinson’s disease.
Table 2 Comparison of characteristics of veterans
with and without a diagnosis of Parkinson’s disease
Characteristic
Per cent of
veterans with
PD
Per cent of
veterans without
PD
(1) Age >65 years 76.26 44.04
(2) Male 97.56 95.18
(3) Race
White 83.42 72.74
Black 7.95 15.52
(4) Employment
Employed 10.08 35.17
Retired 65.86 43.10
Unable to work 22.44 16.55
(5) Education <12th grade 64.47 53.60
(6) VHA priority
4 (catastrophic disability) 8.71 2.64
7 (no disability: co-pay) 9.31 12.77
(7) Source of health care in past three years
VHA only 42.23 34.94
No VHA use 3.15 14.25
Dual use 53.22 45.71
(8) Planned future use of VHA
Primary source 78.16 66.22
Back up 15.11 26.69
Prescription only 5.57 4.12
None 1.16 2.98
(9) Takes no regular exercise 57.77 35.89
(10) Physical health worse than
one year ago
56.98 39.36
(11) Emotional health worse than
one year ago
37.80 26.89
(12) Enrolled in Medicare 78.80 52.30
With private insurance (no
Medicare)
4.44 19.13
Rely 100% on VHA outpatient
care
45.07 33.16
Differences are significant for all characteristics (p < 0.001).
Data were calculated from the 1999 VHA large national health
survey of veteran enrollees.
Items 1–11 were drawn from the core questionnaire (n = 887 775, of
which 14 530 (1.64%) had a diagnosis of Parkinson’s disease). Item
12 was taken from the insurance and utilisation module (n =
152 253, of which 2335 (1.53%) had Parkinson’s disease).
PD, Parkinson’s disease.
Table 3 Self reported co-morbidities and unadjusted
component summary scores of veterans with and
without Parkinson’s disease
Self reported co-morbidity
Per cent of
veterans with
PD
Per cent of
veterans
without PD
Angina/coronary heart disease 25.05 18.55
Arthritis 58.01 50.10
Benign prostatic hypertrophy 35.64 23.15
Cancer 14.66 10.83
Chronic low back pain 42.87 39.86
Chronic lung disease 21.83 19.26
Congestive heart failure 20.49 13.29
Depression 42.80 29.40
Diabetes 21.33 18.74
Hypertension 52.96 49.57
Myocardial infarction 20.01 15.36
Post-traumatic stress disorder 17.66 14.02
Schizophrenia 6.15 4.12
Spinal cord injury 4.60 3.62
Stroke 19.39 8.65
Mean number of chronic conditions 4.03 3.19
Unadjusted physical component
summary (PCS)
30.09 37.01
Unadjusted mental component
summary (MCS)
39.42 45.16
Difference are all significant (p < 0.001).
Data were calculated from 1999 VHA large national health survey of
veteran enrollees, core module, n = 887 775, of which 14 530
(1.64%) had a diagnosis of Parkinson’s disease.
PD, Parkinson’s disease.
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Relative burden of Parkinson’s disease
After adjusting for age, sex, race, education, and 15 self
reported co-morbidities, the mean PCS and MCS scores of
veterans with Parkinson’s disease were lower than those of
veterans with seven other chronic conditions by one to three
points (table 4, columns 4 and 7). Subjects with spinal cord
injury had a slightly lower mean PCS score than subjects with
Parkinson’s disease (32.38 v 32.72; 0.03 of 1 SD). Depression
patients had a markedly lower mean MCS score (35.94 v 41.48;
0.55 of 1 SD).
Unique effects
The adjusted PCS and MCS scores of veterans with
Parkinson’s disease were, respectively, 4.10 and 3.42 points
(0.41 and 0.34 of 1 SD) lower than those of veterans who did
not have Parkinson’s disease (table 4, columns 6 and 9). Three
other diseases had larger unique effects on PCS (arthritis,
−5.44; chronic low back pain, −5.14; spinal cord injury, −4.55),
but subjects self reporting arthritis and low back pain had
higher adjusted PCS scores than subjects with Parkinson’s
disease (34.15 and 33.76 v 32.72). Only depression had a larger
Table 4 The relative health related quality of life of veterans with Parkinson’s disease and self reporting eight other
chronic diseases, adjusted for age, sex, race, education, and 15 co-morbid conditions
Chronic condition
(1)
Per cent of core
population
(weighted n)*
(2)
Mean (SD)
number of self
reported chronic
conditions
(3)
Mean (SE) physical
component summary score Mean effect of
condition on
PCS in points†
(SE)
(6)
Mean (SE) mental
component summary score Mean effect of
condition on
MCS in points†
(SE)
(9)
With
condition
(4)
Without
condition
(5)
With
condition
(7)
Without
condition
(8)
Spinal cord injury 3.6% 5.10 32.38 36.93 −4.55 44.00 44.89 −0.89
(116 189) (0.006) (0.069) (0.013) (0.070) (0.075) (0.014) (0.077)
Depression 29.6% 4.96 35.88 37.17 −1.29 35.94 48.89 −12.95
(946 693) (0.005) (0.026) (0.017) (0.033) (0.030) (0.018) (0.038)
Parkinson’s disease 1.2% 4.01 32.72 36.82 −4.10 41.48 44.91 −3.42
(39 405) (0.024) (0.096) (0.013) (0.096) (0.106) (0.014) (0.107)
Congestive heart
failure
13.4% 6.39 33.68 37.25 −3.57 42.78 45.19 −2.41
(428 538) (0.007) (0.035) (0.014) (0.038) (0.040) (0.015) (0.044)
Stroke 8.8% 5.82 33.69 37.06 −3.37 43.13 45.03 −1.89
(281 760) (0.009) (0.041) (0.013) (0.06) (0.046) (0.014) (0.048)
Chronic low back pain 39.9% 4.60 33.76 38.89 −5.14 43.67 45.70 −2.04
(1 276 539) (0.004) (0.021) (0.018) (0.028) (0.023) (0.019) (0.031)
Arthritis 50.2% 4.46 34.15 39.59 −5.44 44.57 45.16 −0.59
(1 606 481) (0.003) (0.018) (0.020) (0.028) (0.020) (0.021) (0.030)
Diabetes 18.8% 5.06 35.04 37.18 −2.14 44.22 45.01 −0.79
(600 805) (0.006) (0.028) (0.014) (0.031) (0.031) (0.015) (0.034)
Angina/coronary
heart disease
18.6% 5.94 35.49 37.07 −1.58 44.66 44.85 −0.25
(596 323) (0.005) (0.032) (0.015) (0.037) (0.039) (0.016) (0.041)
*Total weighted core population, 3 199 209.
†An effect size of −4.55 is equivalent to 0.46 of one standard deviation.
All coefficients are significant at p < 0.001.
MCS, mental component summary score of the short form-36 questionnaire; PCS, physical component summary score.
Table 5 The independent effects of age, sex, race, and education on health related quality of life, controlling for
Parkinson’s disease and 15 self reported co-morbid conditions
Independent variable
Per cent of core
population Weighted n*
Physical component summary Mental component summary
β SE p Value β SE p Value
Age 18 to 50 years 25.8% 824 213 1.821 (0.041) † −3.244 (0.044) †
51 to 64 years 29.7% 950 155 0.959 (0.031) † -1.755 (0.033) †
>65 years 44.5% 1 422 415 0.000 (0.000) 0.000 (0.000)
Total 100.0% 3 196 784
Sex Male 95.2% 2 914 712 −0.048 (0.069) 0.486 −0.935 (0.074) †
Female 4.8% 146 518 0.000 (0.000) 0.000 (0.000)
Total 100.0% 3 061 230
Race White 72.9% 2 237 175 0.266 (0.041) † 1.237 (0.045) †
Black 15.4% 473 000 −0.323 (0.052) † 0.286 (0.058) †
Other 11.7% 359 036 0.000 (0.000) 0.000 (0.000)
Total 100.0% 3 069 211
Education <12 years 53.8% 1 584 082 −1.981 (0.027) † −2.479 (0.029) †
>12 years 46.2% 1 362 705 0.000 (0.000) 0.000 (0.000)
Total 100.0% 2 946 787
*Total weighted core population, 3 199 209, but data are incomplete for some variables.
†p < 0.001.
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negative impact on MCS than Parkinson’s disease (−12.95 v
−3.42; 1.3 v 0.34 of 1 SD).
The independent effects on PCS and MCS of age, sex, race,
and education are shown in table 5. Men had a lower MCS on
average by 0.94 of a point than women. Younger age groups had
higher mean PCS scores (by one to two points) and lower mean
MCS scores (by 1.75 to 3.24 points) than subjects aged over 65
years. Having no education beyond high school reduced PCS
and MCS scores by 1.98 and 2.48 points, respectively.
DISCUSSION
The analysis quantifies the extent of the negative impact of
Parkinson’s disease on HRQoL, as measured by the V/SF-36,
controlling for the effect of four sociodemographic variables
and 15 co-morbid conditions. The results confirm that people
with Parkinson’s disease carry a relatively heavy illness
burden in both physical and mental dimensions of HRQoL
compared with those suffering from eight other neurological
or chronic conditions.
After removing the effect of sociodemographic factors and
other diseases, the PCS and MCS scores for veterans with Par-
kinson’s disease were lower than those for veterans with
angina/coronary heart disease, arthritis, diabetes, chronic low
pack pain, congestive heart failure, and stroke. Only subjects
with spinal cord injury and depression recorded a lower
HRQoL than those with Parkinson’s disease. Individuals with
spinal cord injury had mean PCS scores that were slightly
below (by 0.34 points) those of the Parkinson’s disease
subjects, but their mean MCS scores were 2.52 points higher.
On average, the MCS of subjects with depression was 5.44
points lower than that of subjects with Parkinson’s disease,
although their mean PCS was 3.16 points higher. The
relatively low HRQoL of subjects with Parkinson’s disease was
not surprising, given the plethora of physical and social prob-
lems attributed to this disease.34
The unique effect of Parkinson’s disease is to lower PCS by
an average of 4.10 points below that of people without a diag-
nosis of Parkinson’s disease. Although chronic low back pain
and arthritis imposed larger negative effects on the physical
dimensions of HRQoL than Parkinson’s disease, the mean PCS
scores for those conditions were higher. Many people with
Parkinson’s disease suffer these co-morbidities (43% and 58%
with self reported chronic low back pain and arthritis in the
VHA large national health survey, respectively).
Only depression had a larger unique effect on mental health
dimensions of HRQoL than Parkinson’s disease, and markedly
so (−12.95 v −3.42; a difference equivalent to almost 1 SD).
Recent international evidence confirms that depression has a
major effect on the HRQoL of people with Parkinson’s
disease,20 22 35 36 but the debate as to whether depression in this
disorder is reactive or endogenous remains unresolved.37 38 If
depression is triggered by the same biological mechanisms
that cause Parkinson’s disease, the logic of calculating
independent effects for both Parkinson’s disease and depres-
sion might be questioned. We therefore repeated our
regression analyses for PCS and MCS controlling for the same
four sociodemographic variables and for a diagnosis of
Parkinson’s disease, but replacing the 15 individual co-
morbidities with a count of the co-morbidities reported by
survey respondents.
This revised specification does not show disease relativities,
and compared with the extended models it reduces explana-
tory power (R2 of PCS, 28.1% v 33.1%; MCS, 22.3% v 38.7%).
The results of the reduced model (not reported here in full)
showed that the mean impact of one chronic disease was to
lower HRQoL by about 0.25 of 1 SD (PCS, β −2.678, SE 0.006,
p < 0.001; MCS, β −2.540, SE 0.006, p < 0.001). The impact of
age, sex, race, and education were very similar to those in the
extended version.
Removing adjustment for individual diseases had very little
effect on mean PCS of veterans with Parkinson’s disease or on
the associated effect size coefficients (32.93 v 32.72; −3.90 v
−4.10 in the reduced and extended models, respectively).
However, when depression was not explicitly controlled for,
the mean MCS of subjects with Parkinson’s disease fell by
nearly two points (from 41.48 to 39.56), and the negative
unique effect of Parkinson’s disease became −5.37 (compared
with −3.42). This is not surprising given that depression is a
major determinant of MCS, 43% of survey respondents with
Parkinson’s disease self reported a previous diagnosis of
depression, and the mean MCS, of subjects with depression
was lower than that of subjects with Parkinson’s disease by a
considerable margin. It has been shown that people with Par-
kinson’s disease adapt differently to their illness, depending
on their physical status, psychological attitude, and social
support.39 40 While there is no simple relation between disabil-
ity and depression,41 coping and behavioural strategies may
reduce depressive symptoms.42 43
Published reports have shown that the MOS version of the
SF-36 is psychometrically sound for measuring HRQoL of
people with Parkinson’s disease. More advanced disease stage
(measured by the unified Parkinson’s disease ranking scale
and the Hoehn and Yahr index), and complications such as
dyskinesia, have been associated with lower SF-36 component
and scale scores. Also, few floor or ceiling effects were found
when SF-36 was used with people with Parkinson’s
disease.9 44 45 Moreover, high correlations have been recorded
between SF-36 and similar scales on the disease specific
PDQ-39.46
There are several limitations to this study. First, it was a
cross sectional sample and therefore the associations between
variables described were purely descriptive and cannot imply
causality. Second, co-morbidities and HRQoL were self
reported, and correlated error may inflate the regression coef-
ficients in some of these models and exaggerate the unique
effects. However, the magnitude of the impact of co-
morbidities on HRQoL has been described previously and our
results corroborate those findings.27 Third, there are selection
effects arising because patients chose to use the VHA. We do
not have internal data to model those effects, so adjustments
for age or other demographics may be biased. However, the
coefficients generated in the models presented are not all that
different from those reported using a non-VHA population.17
The VHA population is different in many respects from the
general populations, including the predominance of service
related occupations and of male enrollees. The VHA popula-
tion (mean PCS, 36.91; MCS, 45.08) carries a greater disease
burden than the US civilian population (mean PCS, 43.60;
MCS, 52.30) by more than one half of 1 SD.19 Moreover, the
distribution of illness is different in VHA in that younger
groups in VHA have worse SF-36 scores in all but the physical
functioning scale.27 A community based study that used SF-36
to investigate the HRQoL of 228 people with Parkinson’s
disease in Finland found that women scored significantly
lower than men in five of the scales, and confirmed the central
role of depression in impairing HRQoL.46
Some observers have noted that people with chronic
diseases rate their HRQoL higher than their physicians.47 In
this regard, the concept of response shift has received
attention.48 Like the disability paradox,49 it refers to the possi-
bility that people with chronic illnesses adjust their internal
standards and values to accommodate the realities of their
condition. It is suggested that they recalibrate their assess-
ment of disability50 and, as a result of lowered expectations,51
they self report a higher quality of life than a healthy person
would assign to any given level of impaired functioning.
Existing measures of HRQoL do not show response shift
because they do not relate self reported experiences to
expectation.52 To the extent that it occurs, response shift
depresses disease effect sizes which are calculated as the
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difference between a clinical group and the general popula-
tion. It is unimportant in intercondition comparisons,
however, unless it has differential impact across diseases.
Conclusions
Despite differences between the VHA and non-VHA popula-
tions, the proportion of people with Parkinson’s disease in the
VHA (1.6%) is equivalent to broader population estimates.53
Other American evidence, based on a sample of 193 individu-
als with Parkinson’s disease completing SF-36 in an out-
patient setting, confirms that most subjects had lower scores
than the general public on most dimensions, but showed that
PCS, and to a lesser extent MCS, varied with disease
severity.9 45 54 The scores calculated in the present study are
averages, and closer inspection of available data is required to
see how generic self reported HRQoL in the VHA population
varies with clinical indicators and service utilisation. The
findings so far suggest, however, that the relative illness bur-
den of veterans in the VHA with Parkinson’s disease is high in
both physical and mental dimensions of HRQoL, and thereby
reinforce the case for multiprofessional team approaches to
management.55 56
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HISTORICAL NOTE...........................................................................................
Pick’s disease
Arnold Pick (1851–1924)
1 was born of German-Jewish parents on
20 July 1851 in Velké Mezirici, in Moravia.2 He studied medicine
in Vienna, where Theodore Meynert (1833–1892) stimulated his
neurological interests. As with many medical scholars of his time, he
was trained in clinical neurology, psychiatry, and neuropathology, a
wide spectrum of disciplines now seldom feasible. In 1874 he trained
in Berlin with Westphal, and from 1875 he worked at the later
infamous asylum of Wehnen. Then he became lecturer in neurology
and psychiatry in Prague where he met Otto Kahler, with whom he
published papers on oculomotor palsies, cortical localisation, and
syringomyelia. They established ‘Kahler-Pick’s law’—incoming fibres
in the posterior columns of the cord from a higher level displace
medially those that enter at a lower level.
He found promotion to the chair of neuropsychiatry in Prague but
encountered many problems related to academic teaching in both
German and Czech languages, controlled by the Austro-Hungarian
empire. Essential provisions were often lacking and he met with much
hostility and resentment1 that often hampered his work. Despite this,
his remarkable ability to communicate with patients with psychoses
and aphasia was admired, and his history-taking became legendary.
An intellectual man, Pick loved classical music and in his home his
books in many languages were piled from floor to ceiling. He was
described as a “noble minded, excessively modest but fearless man,
the essence of calm serenity”.2 He retired in 1921, but continued some
work, despite troublesome cataracts and urinary tract stones. On 4
April 1924, at the age of 73, he died of urinary sepsis following blad-
der surgery.
Pick published about 350 papers on diverse topics. Many were case
reports dealing with neuropsychology and behavioural neurology. He
was among the first to give reliable descriptions of visual hallucina-
tions, micrographia, palilalia, and reduplicating paramnesia. He wrote
important papers on apraxia and aphasia.3 He described the fibre
bundles in the medulla oblongata (Pick’s bundle). His 1898 book on
neuropathology was a landmark in this field.4
In his work on aphasia he introduced the term agrammatism.
Agrammatical speech was the basic defect of aphasic disorders. Wer-
nicke influenced his views on language but Jackson probably had a
greater influence on his concepts of how language was disrupted.
They had great mutual respect and shared a distaste for speculation;
both wrote in terse prose.
Pick’s disease
In 1892, Pick described a 71 year old man who presented with
progressive loss of language and a failing mind.5 After death, the brain
showed asymmetrical atrophy as opposed to the more diffuse atrophy
of Alzheimer’s disease. The condition described by Pick “on the rela-
tionship between senile atrophy of the brain and aphasia”6 was often
confused with Alzheimer’s and vascular dementias. Pick published
three further papers, in which he showed patients with severe apha-
sia and apraxia who had a “progressive circumscribed atrophy” of the
cortex.7–9 He regarded these patients as suffering from a variant of
senile dementia. Attention was drawn to the aphasic and later the
apraxic side of the syndrome, but eventually the distinctive pathology
established it as an entity.
Alzheimer in 1911 confirmed the circumscribed cortical (lobar)
atrophy,10 and found the characteristic Pick bodies: ovoid, homogene-
ous, smooth-edged, and intensely argyrophilic neuronal inclusions.
Gans introduced the name Pick’s disease in 1922.11
J M S Pearce
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